1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Euromedis Groupe

Euromedis Groupe

ALEMG.PA
Euromedis Groupeundefined flagEuronext Paris
4.88
EUR
- -
- -
13.94MMarket Cap
Euromedis Groupe
ALEMG.PA
(Euronext Paris)

Recent

price

4.88

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2019
2020
2021
2022
2023
2024
2025
FRC
26.81
26.79
22.02
24.86
25.3
23.87
23.8
24.46
24.61
25.79
64.28
37.17
18
11.95
12.73
- -
Revenue per Share
-1.05
0.34
-0.27
0.36
0.73
0.85
0.83
0.34
-0.05
-1.22
7.53
0.75
-1.97
4.6
-2.15
- -
Basic EPS, GAAP
-2.7
1.12
-0.61
1.06
0.44
0.75
0.28
0.03
-0.06
-0.78
4.27
5.78
-0.69
- -
- -
- -
Free Cash Flow per Basic Share
0.07
- -
- -
- -
0.01
0.07
0.1
0.12
0.09
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.18
4.53
3.75
4.11
4.83
5.6
6.33
6.55
6.27
0.78
9.53
2.75
0.03
3.48
1.25
- -
Book Value per Share
1.86
2.23
2.42
2.78
3.51
4.28
5.45
5.51
5.27
3.69
11.66
12.78
10.71
6.47
5.73
- -
Tangible Book Value per Share
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
- -
Basic Weighted Avg Shares
64
64
66
74
76
71
71
73
74
77
193
112
54
34
36
41
Sales/Revenue/Turnover
-4.03
3.33
-0.9
3.05
4.61
5.58
4.7
1.77
-0.33
-3.13
14.64
3.31
-10
-12.52
3.62
1.61
Operating Margin (%)
1
1
1
1
1
2
2
2
2
1
5
-2
1
-3
-3
-1
Depreciation Expense
-3
1
-1
1
2
3
2
1
- -
-4
23
2
-6
13
-6
- -
Net Income, GAAP
- -
36.1
- -
38.97
30.15
30.17
18.97
9.2
- -
- -
19.38
8.4
- -
1.24
- -
123.93
Effective Tax Rate (%)
-3.93
1.26
-1.24
1.45
2.9
3.58
3.47
1.38
-0.2
-4.73
11.72
2.02
-10.95
38.52
-16.87
-0.32
Profit Margin (%)
6
8
6
5
8
10
13
13
12
12
49
51
42
30
27
27
Working Capital
- -
4
3
2
2
2
2
2
2
7
16
15
13
10
8
6
LT Debt
18
18
20
21
23
26
29
29
28
16
39
41
35
23
16
16
Total Equity
- -
5.83
- -
4.4
6.48
7.21
6.81
2.87
- -
- -
44.88
5.66
- -
-10.4
- -
-0.66
Return on Invested Capital (%)
- -
5.25
- -
6.86
9.77
10.53
9.85
4.21
- -
- -
66.16
7.14
- -
81.51
- -
-2.05
Return on Capital (%)
- -
7.76
-7.38
9.19
16.44
16.37
13.86
5.23
-0.76
-34.58
146.14
12.21
-141.85
262.07
-90.72
-3.77
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.73%
-14.44%
-0.46%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
48.12%
-203.69%
-97.84%
Sales/Revenue/Turnover
4.7%
-22.34%
12.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
34
2024
- -
- -
- -
- -
36
2025
- -
- -
- -
- -
41

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.6
2024
- -
- -
- -
- -
-2.15
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
InhaleRx Limited (IRX.AX)
ALR Technologies Inc. (ALRTF)
NeoDynamics AB (publ) (NEOD.ST)
Hamilton Thorne Ltd. (HTLZF)
Imaging Dynamics Company Ltd. (IDYLF)
Ningbo David Medical Device Co., Ltd. (300314.SZ)
Business
Laboratoires Euromedis Société anonyme (ALEMG.PA), founded in 1985 and headquartered in Neuilly-sous-Clermont, France, designs, manufactures, imports, distributes, and rents medical and surgical equipment under the Euromedis brand for healthcare professionals, hospitals, clinics, retirement homes, local communities, and individual patients primarily in France and internationally; core products include sterile and non-sterile medical gloves (including Finessis Zero, Maxitex Neuro PF, and Nuzone x2 polychloroprene variants), dressings and compresses, medical sets, parenteral approach devices such as needles, syringes, infusers, and catheters, wound drainage products, operating theater probes and draping ranges, surgical gloves, protective covers, oxygen therapy equipment, incontinence and hygiene products, diagnostic tools, and home care products, with additional services encompassing home infusion and nutrition under the PARAMAT and MEDIS SANTE brands as well as vehicle and equipment rental for the physically handicapped. The company operates in the medical devices and home healthcare sectors, serving public and private health facilities with single-use consumables and assistance services. In late 2024, it successfully launched and completed an issuance of convertible bonds with warrants (OCA) while maintaining the shareholders' pre-emptive right, adjusted its liquidity contract, and released its 2024 full-year and interim results alongside the 2025 semestriel financial report.